StockNews.com initiated coverage on shares of BioLineRx (NASDAQ:BLRX – Get Rating) in a research report released on Thursday morning. The firm issued a sell rating on the biotechnology company’s stock.
BioLineRx Stock Performance
Shares of NASDAQ BLRX opened at $0.61 on Thursday. The company has a quick ratio of 7.12, a current ratio of 7.12 and a debt-to-equity ratio of 0.15. BioLineRx has a 1 year low of $0.55 and a 1 year high of $1.98. The firm’s 50-day moving average is $0.63 and its 200-day moving average is $0.79.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently bought and sold shares of the company. Virtu Financial LLC boosted its stake in BioLineRx by 195.6% during the 3rd quarter. Virtu Financial LLC now owns 46,168 shares of the biotechnology company’s stock worth $43,000 after acquiring an additional 30,551 shares during the last quarter. PVG Asset Management Corp bought a new position in BioLineRx during the 3rd quarter worth approximately $44,000. Apollon Wealth Management LLC bought a new position in BioLineRx during the 3rd quarter worth approximately $45,000. Renaissance Technologies LLC boosted its stake in BioLineRx by 49.1% during the 3rd quarter. Renaissance Technologies LLC now owns 68,222 shares of the biotechnology company’s stock worth $63,000 after acquiring an additional 22,478 shares during the last quarter. Finally, LPL Financial LLC boosted its stake in BioLineRx by 152.7% during the 4th quarter. LPL Financial LLC now owns 117,710 shares of the biotechnology company’s stock worth $69,000 after acquiring an additional 71,134 shares during the last quarter. Institutional investors own 18.15% of the company’s stock.
BioLineRx Company Profile
BioLineRx Ltd. is a clinical stage biopharmaceutical company, which focuses on oncology. Its pipeline includes Motaxafortide (BL-8040), which is used for stem-cell mobilization, solid tumors, and acute myeloid lukemia; and AGI-134, which is a immunotherapy treatment used fro multiple solid tumors. The company was founded in 2003 and is headquartered in Modi’in, Israel.
- Get a free copy of the StockNews.com research report on BioLineRx (BLRX)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for BioLineRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx and related companies with MarketBeat.com's FREE daily email newsletter.